Phase I
The first four patients that were administered BS01, Bionic Sight’s investigational gene therapy for advanced retinitis pigmentosa (RP), all reported the ability to detect light and motion. Two of the patients were also able to detect direction.
Disappointing data from two Phase Ib/IIa trials for both lead Huntington’s disease antisense candidates have pushed Wave Life Sciences to shelve the assets and focus on its next generation of therapies.
Between the Moderna and Pfizer-BioNTech COVID-19 vaccines, there are two mRNA therapeutics on the market … the only two.
There was a fair amount of clinical trial news last week. Here’s a look.
Meissa Vaccines’ intranasal live attenuated chimeric virus-based vaccine for SARS-CoV-2 (and its variants) recently was cleared for Phase I trials, which will start at the end of March.
With the rise of mutant strains of SARS-CoV-2 and the unlikelihood of 100% compliance in getting vaccines out, investigators are focusing on developing even better vaccines and new drugs that might be able to knock back the disease. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 23, 2021.
A COVID-19 nasal spray vaccine developed by Rokote Laboratories Finland Ltd., is preparing for Phase I trials in Finland…if it can win funding.
It was a relatively quiet week in terms of clinical trial news, but there were some significant releases. Here’s a look.
Findings from a second interim analysis of a first-in-human Phase I/II clinical trial of Translate Bio’s CF mRNA candidate, MRT5005, show the drug did not significantly improve lung function in patients with CF.
PRESS RELEASES